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ABSTRACT
As an alternative modality to conventional radiotherapy, electrons with energies above 50 MeV penetrate deeply
into tissue, where the dose can be absorbed within a tumour volume with a relatively small penumbra. We
investigate the physical properties of VHEEs and review the state-of-the-art in treatment planning and dosimetry.
We discuss the advantages of using a laser wakefield accelerator (LWFA) and present the characteristic features of
the electron bunch produced by the LWFA and compare them with that from a conventional linear accelerator.
Keywords: very high energy electrons (VHEEs), radiotherapy, depth-dose distribution, laser wakefield acceler-
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1. INTRODUCTION
Intensity-modulated radiotherapy (IMRT) using X-rays between 4 and 22 MeV is currently the most flexible
method of delivering a high radiation dose to a target volume while simultaneously protecting adjacent sensitive
tissue. IMRT spreads the dose over a large volume of healthy tissue while concentrating maximum dose within
the tumour volume. However, its efficacy is still questioned by some1 and it carries an increased risk of radiation
induced malignancy.2,3 In contrast, advanced radiotherapy modalities such as proton and ion beam therapies
have been shown to be effective because of the combination of their high penetration, favourable dose distribu-
tions within tissue, and increased radiobiological effectiveness. However, their cost is currently considered too
high for wide availability because large infrastructures are required to transport beams to the patient.4 Recent
investigations have shown that electrons with increased energy (up to 50 MeV) feature favourable dose distri-
butions, particularly in combination with photon beams.5–7 Very high energy electron (VHEE) therapy using
electron beams up to 250 MeV was first considered by DesRosiers et al.8,9 as a viable and cost-effective alter-
native to intensity-modulated radiation therapy (IMRT) with photon and proton beams. Theoretical studies,
based on the Monte Carlo (MC) methods, have demonstrated that VHEEs provide an implicit tool for scanning
deep-seated lesions. The dosimetric characterisation of VHEE beams has already been performed in previous
work.10–15 These studies conclude that main secondary products of the VHEE interactions with water molecules,
neutrons and protons, should not significantly affect equivalent doses in comparison with photon treatments.
The treatment planning comparison studies provide necessary information for introduction of new radiother-
apy modalities into clinical practice. Monte Carlo-aided simulations16–21 were carried out towards assessment of
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treatment planning with VHEEs. The lower ratio of total dose to the target dose, higher dose rates (Gy/s) and
therefore better conformity to the tumour volume and tissue sparing, comparable to traditional photon therapy
with energies 6 and 16 MV, have been investigated and reported. Utilising the voxel-PENELOPE engine code
as a preliminary treatment planning system (TPS) for very high energy electron therapy (VHEET) has been
recently proposed.15,20 This is a significant move towards building a tool allowing further comprehensive studies
for designing and planning of future VHEET systems. Yeboah and Sandison, following the current trends in
radiotherapy quantified the performances of treatment plans using VHEEs versus photon and proton therapy.
They have shown that the probability of complication-free tumour control for clinically relevant treatment plans
decreases in the following order; intensity-modulated proton therapy (IMPT), VHEET and intensity-modulated
X-ray therapy (IMXT), respectively.22 The feasibility of using intensity modulated VHEET and VHEE Pen-
cil Beam Scanning (PBS) have been explored in more detail.15,23 The present research on VHEEs aims to
investigate technical features, treatment quality, delivery and manipulation of VHEEs.24–27 To improve dose
distribution and examine the radiobiological effectiveness (RBE) of VHEEs have yet to be explored.
2. CURRENT RADIOTHERAPY MODALITIES VS. VHEES
Figure 1 presents Monte Carlo calculated percentage depth dose (PDD) curves in 30 × 30 × 30 cm3 water
phantom for various types of radiation with 10 × 10 cm2 field size. Megavoltage photons (1a), due to the rapid
increase to a peak dose in the shallow depths, produce low surface dose causing less damage to the skin. In
IMRT the number of beam portals arranged in several angles around the patient, is used to create a dose plateau
deep inside the tissue and a sharp dose contrast at the tumour edge (1b).
Clinical electron beams with energies in the range of 4–25 MeV (1c) have finite penetration range in tissue,
after which the dose falls off rapidly. As such, this radiation modality is suitable for treatment of superficial
lesions, and rarely in intraoperative radiotherapy to provide a boost to the tumour bed. Sub-cutaneous and
visceral cancers are treated with electrons in this energy range in combination with megavoltage photon beams.28
Protons and heavy ions (150 – 300 MeV) deposit most of their energy into a narrow region known as the
Bragg peak (1d). Therefore, these beams have tremendous advantage over X-rays allowing precise localisation of
dose in a tumour. The uniform dose region, in the longitudinal direction, referred to as Spread-out-Bragg Peak
(SOBP) (1e), can be achieved by integrating the planar dose distributions created by altering the initial proton
energy at the accelerator source. A high level of entrance dose results from the superposition of several narrow
mono-energetic pencil-shaped beams during intensity modulated proton therapy (IMPT).
The depth of maximum dose deposited by 150 MeV electron beams (1f) already exceeds the depth of most
deep-seated tumours (>10 cm). For depths ≤ 5 cm VHEEs have been proven to exhibit penumbrae comparable to
photons,9 and more uniform dose distribution at larger depths. VHEEs do not exhibit significant perturbations
when propagating through tissues of varying densities, unlike photons9 and protons,29 which abruptly scatter
and dissipate the dose within surrounding tissue. The dose distribution can be shaped by using non-overlapping
multiple beams similar to those found in the IMRT scheme. For particle beams the probability of scattering
events increases with depth. Electrons transfer most of their energy to tissue at the end of their range similar to
protons. However the most intense scattering, at the Bragg peak, takes place beyond the patient since VHEEs
exit the tissue before they terminate propagation.
3. LASER PLASMA VS. CONVENTIONAL ACCELERATORS
Over the past decade, significant efforts have been made to develop complex beam geometries and control the
particle and radiation beams transport employing superconducting magnets.30–32 Additionally, this technology
enables to produce more compact sources. However, the size of hadron therapy centres still remains large because
of immense gantries required to transport the beam, long beamlines and extensive shielding. All of these translate
into high construction and running costs. For instance, the price of building proton centre is 40 times higher
than for LINAC X-ray facility.33 Therefore access to hadron therapy is limited what stimulates a search for more
compact types of accelerators and alternative radiation modalities.
Very high energy electron therapy, proposed by DesRosiers et al.8 has a potential of becoming new radiation
treatment method due to dosimetric advantages over conventional X-rays. However, the high cost and size of
Figure 1. The percentage depth-dose distribution for different types of radiation: photons 6 MV (a), superposition
of 25 MV parallel opposed photon beams and perpendicular beam (b), 10 MeV electrons (c), protons 160 MeV (d)
spread-out-Bragg-peak (e), 150 MeV electrons (f).
LINAC-based VHEE accelerators has thwarted progress in developing the VHEE modality. In 1979 Tajima
and Dawson34 introduced the concept of Laser Wakefield Acceleration (LWFA). This technology offers a much
more compact accelerator footprint, requiring sufficient laser technology as the main driver. The development of
table-top laser systems allows the true potential of LWFA to be explored. In 2004, three independent research
groups35–37 used the LWFA concept to demonstrate a new type of accelerator based on laser-driven plasma
waves. In laser-plasma wakefield accelerators (LWFAs) background plasma electrons are trapped in the LWFA
plasma bubble “structure” and get accelerated coherently to extremely high energies over several millimetres.
High quality, mono-energetic, ultra-short duration, high peak current electron bunches are produced simply by
placing a supersonic hydrogen or helium gas jet at the focus of an ultra-short pulse terawatt (TW) laser beam.38
Figure 2. Electron bunch trapped in plasma cavity created behind the laser pulse during wakefield acceleration.
Typically 1018– 1019 electrons/cm3 provide the space-charge fields of plasma of the order of 100 GV/m, which
is roughly 1000 times higher than in cavities of conventional accelerators.39 This allows to reduce the size of
a 100–200 MeV accelerator from 10s of metres to just 1–2 mm exceeding currently existing energy limits.40,41
Conventional S-band LINACs typically produce electrons with few microsecond duration macro-pulses formed
of ≈3 GHz micro-pulse trains of 10–35 ps duration and ≈30 pC charge. In contrast, LWFA VHEE electrons
have bunch durations of around 1 femtosecond (10−15 s) at source, charges of ≈10 pC, and δE/E≈1–10% energy
spread.42 They currently operate at a repetition rate of up to 10 Hz, but progress is being made to extend the
rates to 1 kHz (e.g. by using Coherent Amplifying Network (CAN) laser).43
Shortly after first experimental demonstration of the LWFA, these sources were considered as a potential
way of producing VHEEs for radiotherapy.10 Simulations of 170 MeV LWFA electrons were used to investigate
an inverse treatment planning system for intensity-modulated treatments, which showed better target coverage
than 6 MV IMXT.19
An example of an LWFA source used for radiobiology studies is the Advanced Laser-Plasma High-energy
Accelerators towards x-ray (ALPHA-X) project at the University of Strathclyde14. The accelerator beamline
is part of the various dedicated beamlines available across three shielded areas at the Scottish Centre for the
Application of Plasma-based Accelerators (SCAPA). This state-of-the-art centre offers a suite of high peak-power
laser systems to drive accelerators towards unique applications. SCAPA offers 40 TW and 350 TW peak-power
laser systems across a range of accelerator type and technologies. SCAPA 40 TW laser system delivers a laser
pulse of 35 fs pulse duration with a central wavelength of 800 nm at repetition rate up to 10 Hz and energy
of 900 mJ on target and has already been used for dosimetry measurements of VHEEs.11,13 The ALPHA-X
beam line is shown in Figure 3. The SCAPA 40 TW laser beam coming directly from the compressor is focused
at the entrance of a gas-jet by a spherical mirror (with focal length 80 cm). The laser is focused to a focal
spot diameter of 40 µm (1/e2 diameter) into a supersonic helium gas jet. The aberration-free focal spot can
be achieved by proper alignment of the f/18 spherical mirror. When the laser beam interacts with plasma,
electron beams with energy of at least 100 MeV and δE/E≈1% energy spread are produced. A setup of three
miniature permanent magnet quadrupole (PMQ) lenses, are available preventing electron beam blow-up over
long drift propagation as they pass through Lanex screens, used to monitor the transverse beam profile. The
energy spectrum is measured by a spectrometer co-aligned with the beam line axis. Multiple Lanex screens
imaged by high-resolution charge-coupled device (CCD) cameras are available to monitor the electron beam
profile/pointing along the linear beamline.
Figure 3. The ALPHA-X beamline.
The very short duration and high charge density of electron bunches produced by ALPHA-X (in the range
of 5-10 pC) lead to very high energy beams ideally suited to VHEE studies.
4. DOSE RATES AND TREATMENT TIME
Several factors have a strong impact on tumour cell kill and tumour response outcome. Among these, dose rate
and overall treatment time are pertinent and depend on accelerator capabilities. The dose-rate range in external
radiotherapy extends from about 1.8 Gy/hr to several Gy/min and usually varies with the acceleration type,
source to surface distance (SSD), energy and geometry. Commercial medical LINACs operate within dose rate up
to 6 Gy/min while cyclotrons for proton therapy deliver typically 2 Gy in less than 1 min. Patient comfort during
the treatment and treatment accuracy are directly related with radiation treatment time. Treatment duration
is established based on accelerator capabilities (dose rate regime), tolerance dose and recurrence time of normal
cells. A number of studies have shown that early-stage cancer treated with a shorter and more intense radiation
(e.g. accelerated hypofractionated whole breast irradiation) results in fewer side effects than the traditional
six-week course.44–46 The ALPHA-X accelerator is capable to produce a bunch (shot) of electrons with a charge
typically 10 pC carrying 6.25×107 particles corresponding to 0.07 cGy. For a 10 Hz laser system the number of
shots to deliver 2 Gy to the target (water) at 15 cm depth is around 3000, this translates to approximately 5
minutes irradiation time and dose rates around 0.4 Gy/min. Therefore, efforts are being continued to increase the
delivered charge of the produced electron bunches in order to increase dose rates.47 Proton therapy accelerators,
on the other hand, with a built-in gantry systems are currently capable of delivering at a rate of roughly 3000
Bragg peaks per minute (≈ 2 Gy), equivalent to 50 Hz,48 this translates into delivery times per field of between
a few seconds to 20-25 min. The arrangement of two opposite fields escalates the treatment time to 50 min.
5. RADIOBIOLOGY
Two mechanisms of cell kill are commonly identified path-ways in radiobiology: single and double DNA hit
mechanisms. The former is associated to be responsible for sub-lethal DNA double-strand breaks (DSB) and
thus chromosome aberration formation at the micrometre level, whereas the latter causes lethal damage by several
chemical changes to DNA at the nanometre level. Normal tissue complication can result from the inactivation
of stem cells by both mechanisms but tissue architecture or damage to vasculature could also play a role. In
current clinical practice 1.8 – 3 Gy fractions are administrated for 5 days a week, up to the prescribed dose to
the tumour area. The optimal combination of adequate killing of tumour clonogens and the time given to normal
cells for convalescence, fractionation scheme, is decided by oncologist based on specification of the clinical case.
It has been shown that irradiation with low dose rates in many fractions results in reduced cell killing due to fast
proliferation of the tumour cells and enzymatic repair of sub-lesions in the tumour.49 The effects of dose-rates
below the threshold at which micrometer-scale effects are still observable are studied based on the mechanism
of DNA double strand breaks (DSBs), gene mutations, chromosomal aberrations and cell-cycle activation and
apoptosis. The probability of killing the cell depend on the cell phase at the point when radiation is delivered.
The cell is more radiosensitive in phases G2-phase and mitosis. In S phase, when DNA is being replicated, cells
seem more able to repair DNA damage. However, the cell-cycle is a stochastic factor and depends upon the
statistics of the number of cells found in the same phase.
In 1959 Bergonie and Tribondeau50 proved that increased sensitivity to radiation is seen in populations of
cells that are highly proliferative with rapid cell divisions and less differentiated (i.e. stem cells are more sensitive
than mature somatic cells). Tumour cells usually divide faster than normal cells thus there are more sensitive
to radiation. Poorly-differentiated carcinomas are the most aggressive tumours or cancers in their final stage.
Due to uncontrolled proliferation some areas within tumour are isolated from blood vessels and become hypoxic
(more resistant). To achieve uncomplicated local regional control of cancer different types of cells/tissue need to
be treated with various dose rates resulting in improved treatment efficiency. The dose rates which impact the
biological response can be established based on the existing mathematical models; tumour control probability
(TCP) and normal tissue complication (NTCP). The former is a probability of killing tumour cells after a certain
total dose is delivered, whereas the later is defined as the probability that a certain percentage of the patient
population will incure unfavourable side effects at a particular dose. Current LWFA technology, in contrast to
conventional accelerators, are able to vary in repetition scaling (up to 10 Hz) allowing alternating dose rate.
6. FUTURE OUTLINE
The LWFA accelerator is a promising and cost-effective alternative to produce VHEEs. Its compact size is
dictated by the use of a non-ionising radiation source (laser light). Therefore, transport of the laser beam up to
the accelerator head requires no additional shielding unlike in conventional accelerators. Furthermore, instead
of traditional around 2–3 m long arrangement of RF cavities and bending magnets to accelerate and transport
the beam, the gantry of a LWFA accelerator would contain laser optics for guiding the laser beam and the
acceleration would take place in the plasma cell of less than mm41 length mounted in the accelerator head. The
conceptual scheme of the future accelerator was proposed by Nakajima et al.51,52 Additional advantages of the
LWFA design is the possibility to be developed into a multimodal machine. Laser-plasma electron bunches can
be used to produce X-rays and protons through laser-solid target interactions (with the target placed in the
accelerator head). However, production of protons, using laser-plasma technology, is currently very limited due
to low efficiency of energy conversion (around 1%) and, therefore, reduced beam quality.
The laser transport allows the optical geometry to be adapted to transport the laser to various fixed ac-
celerators around the patient (multiple beams) and many treatment rooms (see Figure 4). A new dedicated
beamline at SCAPA will distribute the LWFA produced radiation in a vertical orientation, as opposed to the
LWFA community standard of a horizontal accelerator. Using this layout pioneering radiotherapy cell studies
can be performed in a traditional patient style layout. In addition, SCAPA laser system and current LWFA
technologies are able to vary in repetition scaling (up to 10 Hz) allowing further investigation towards the future
charge/dose rate modulation VHEET.
Figure 4. The conceptual scheme of medical centre for LWFA VHEET.
7. CONCLUSIONS
The ability to produce extremely short electron bunch durations from LWFA can provide a more effective way of
killing cancer cells and reducing treatment time. The key challenges remain to identify the biological mechanisms
following exposure to LWFA VHEE beams to understand their dose and dose-rate responsiveness and manifest
clinically increased tumour control. The designed radiobiological models can be used to estimate the dose rates
which impact the biological response. Based on the existing knowledge VHEEs administrated in the similar way
to IMRT can provide similar tumour conformity and lower entrance dose in treatment of deep-seated tumours.
A combination of compacted, cost-effective technology and favourable dosimetric properties of VHEEs is
a promising alternative which offers multiple options to design high precision, compact and cost-effective ra-
diotherapy modality. Advanced optical technology allows to share one laser beam between multiple rooms in
addition to providing an easy and stable guiding system with no shielding required. The electron beams can be
delivered in a portable mode from robotic arm (similar to Cyber Knife) or gantry (similar to proton therapy but
in more compact way).51,52 We propose a novel solution, the multiaccelerator arrangement in a single treatment
room, which can allow many beams to be delivered at the same time. This mode could significantly reduce the
radiation time and treatment uncertainties compared to X-ray therapy. The additional advantages of LWFA over
conventional LINACs are the capability to produce different types of radiation (electrons, X-rays and protons)
and control beam parameters from the source by changing parameters of the laser and the gas.
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